Structural Heart Devices Market by Product (Heart Valve Devices Transcatheter and Surgical), Occluders, Closure and Delivery Systems, Annuloplasty Rings, Accessories, Procedure (Replacement(TAVR/TAVI)), Repair & End-Users-Global Forecast to 2029
세계의 구조적 심질환용 기기 시장 규모는 2024년 163억 1,000만 달러에서 2029년 256억 9,000만 달러에 이를 것으로 예측되며, 2024년부터 2029년까지의 복합 연간 성장률(CAGR)은 9.5%가 될 것으로 예측됩니다.
구조적 심질환용 기기 시장의 성장 촉진요인으로는 판막증과 선천성 심장 질환의 이환율 상승, TAVR과 TMVR 등의 저침습 기술의 높은 진보율, 세계 인구의 고령화와 헬스케어 인프라 등 강화에 따른 채용률의 상승 등을 들 수 있습니다.
| 조사 범위 |
| 조사 대상년도 |
2022년-2029년 |
| 기준년 |
2023년 |
| 예측 기간 |
2024년-2029년 |
| 검토 단위 |
금액(달러) |
| 부문별 |
절차별, 제품별, 최종 사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 중동 및 아프리카 |
구조적 심질환용 기기 시장에서 가장 중요한 부문은 심장 판막이며, 주된 이유는 특히 고령자층에서 대동맥 판막 협착증과 승모판 폐쇄 부전증과 같은 판막증의 유병률이 높습니다. 이것들은 조기 단계에서의 치료가 필요하며 저 침습 기술의 최신 부 레이크 스루는 TAVR과 TMVR이었고, 이러한 질병의 치료 접근법을 극적으로 변화 시켰습니다. 또는 수술 불능으로 분류되는 환자에 대한 접근의 확대를 제공합니다.
예를 들어, 내구성 향상, 밀폐성 향상 및 전달 메커니즘 최적화와 같은 차세대 밸브와 같은 기술적 업등급는 이 부문의 가장 중요한 수요 드라이버 중 하나가 되었습니다. Lifesciences, Medtronic 및 Abbott의 각 회사는 선진적인 경 카테터 심장 판막의 개발에 많은 투자를하고 있으며,이 부문의 우위를 더욱 강화하고 있습니다. 국가 시장에서 이러한 제품의 채택 확대는 상환 정책의 성장과 입증 된 임상 성공률에 의해 지원되며 심장 판막 부문을 구조 심장 시장에서 가장 크고 가장 빠르게 성장하는 범주로 더욱 견고합니다. 하고 있습니다.
본 보고서에서는 세계의 구조적 심질환용 기기 시장을 조사했으며,, 수기별, 제품별, 최종 사용자별, 지역별 동향, 시장 진출기업 프로파일 등을 정리했습니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 중요 인사이트
제5장 시장 개요
- 소개
- 시장 역학
- 업계 동향
- 고객사업에 영향을 주는 동향/혼란
- 가격 분석
- 밸류체인 분석
- 공급망 분석
- 생태계 분석
- 투자와 자금조달 시나리오
- 기술 분석
- 특허 분석
- 무역 분석
- 2024년-2025년의 주된 회의와 이벤트
- 사례 연구 분석
- 규제 상황
- Porter's Five Forces 분석
- 주요 이해관계자와 구매 기준
- 상환 분석
- 언멧 요구와 최종 사용자의 기대
- AI/생성형 AI가 구조적 심질환용 기기 시장에 미치는 영향
제6장 구조적 심질환용 기기 시장 : 수기별
제7장 구조적 심질환용 기기 시장 : 제품별
- 소개
- 심장 밸브 장치
- 폐색 기구, 폐쇄 시스템 및 전달 시스템
- 환상 형성 링
- 액세서리
제8장 구조적 심질환용 기기 시장 : 최종사용자별
제9장 구조적 심질환용 기기 시장 : 지역별
- 소개
- 북미
- 유럽
- 유럽의 거시 경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타
- 아시아태평양
- 아시아태평양의 거시 경제 전망
- 일본
- 중국
- 인도
- 호주
- 한국
- 기타
- 라틴아메리카
- 라틴아메리카의 거시 경제 전망
- 브라질
- 멕시코
- 기타
- 중동 및 아프리카
- 중동 및 아프리카의 거시경제 전망
- GCC 국가
- 기타
제10장 경쟁 구도
- 소개
- 주요 진입기업의 전략/강점
- 수익 분석(2019년-2023년)
- 시장 점유율 분석(2023년)
- 기업평가 매트릭스 : 주요 진입기업(2023년)
- 기업평가 매트릭스 : 스타트업/중소기업(2023년)
- 브랜드/제품 비교
- 기업이치평가와 재무지표
- 경쟁 시나리오
제11장 기업 프로파일
- 주요 진출기업
- EDWARDS LIFESCIENCES CORPORATION
- MEDTRONIC
- ABBOTT
- BOSTON SCIENTIFIC CORPORATION
- TELEFLEX
- INTEGER HOLDINGS CORPORATION
- LEPU MEDICAL TECHNOLOGY CO. LTD.
- TTK HEALTHCARE
- ARTIVION, INC.
- VENUS MEDTECH(HANGZHOU) INC.
- LIFETECH SCIENTIFIC CORPORATION
- COOK
- CORDIS
- SMT
- MERIL LIFE SCIENCES PVT. LTD.
- WL GORE & ASSOCIATES, INC.
- 기타 기업
- FOLDAX
- MICRO INTERVENTIONAL DEVICES, INCORPORATED
- CARDIAC DIMENSIONS
- BIOTRONIK
- HIGHLIFE MEDICAL
- MITRALIGN
- BRAILE BIOMEDICA
- JENAVALVE
- CORCYM
- XELTIS
- INNOVHEART SRL
제12장 부록
BJH
The global Structural heart devices market is projected to reach USD 25.69 billion by 2029 from USD 16.31 billion in 2024, at a CAGR of 9.5% from 2024 to 2029. Drivers of growth in the market for structural heart devices include mounting incidence rates of valvular and congenital heart diseases, high advancement rates of minimally invasive technologies such as TAVR and TMVR, and rising adoption rates since global populations are aging and healthcare infrastructure is being enhanced.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD) |
| Segments | By Product, Procedure, End Users and Region |
| Regions covered | North America, Europe, APAC, LATAM, MEA |
"By product segment Heart Valve segment to account for the largest share during the forecast period"
The most paramount segment of the structural heart devices market is heart valves primarily due to the higher prevalence of valvular diseases such as aortic stenosis and mitral regurgitation, especially in the geriatric population. These have treatment requirements at the earlier stages, with the latest breakthroughs in minimally invasive techniques being TAVR and TMVR, which have drastically altered the approach to treating these diseases. The above techniques offer reduced recovery times, fewer surgical risks, and greater access to patients classified as high-risk or inoperable when compared to traditional open-heart surgery.
Technological upgrades, for example, next-generation valves with improved durability, better sealing, and optimized delivery mechanisms form one of this segment's most important demand drivers. Edwards Lifesciences, Medtronic, and Abbott companies are heavily investing in developing advanced transcatheter heart valves, thus further strengthening the dominancy of the segment. In addition, the growing adoption of these products in developed and emerging markets, supported by growth in reimbursement policies and demonstrated clinical success rates, further solidifies the heart valve segment as the largest and fastest-growing category in the structural heart market.
"APAC is estimated to register the highest CAGR during the forecast period."
The Structural heart devices market is divided into Five regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The Asia Pacific region witnessed the highest CAGR during the forecast period. Many APAC countries, including Japan, South Korea, and China, are witnessing demographic shifts as their populations age. The increasing diabetic population and increase in obesity due to sedentary lifestyles are also driving the growth of Structural heart devices in the APAC region.
The breakdown of the profile of primary participants in the Structural heart devices market:
- By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
- By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
- By Region: North America - 40%, Europe - 30%, APAC -20%, Latin America - 5%, Middle East & Africa-5%
List of Companies Profiled in the Report
- Boston Scientific Corporation (U.S)
- Edwards Lifesciences Corporation (U.S)
- Medtronic (Ireland)
- Boston Scientific Corporation (U.S
- Abbott (U.S)
- Teleflex (U.S)
- Integer Holdings Corporation (U.S)
- Lepu Medical Technology Co.Ltd.(China)
- TTK (India)
- Artivion, Inc. (U.S)
- Venus Medtech, Inc. (China)
- Cook (U.S)
- SMT (India)
- Meril Lifesciences Pvt.Ltd (India)
- W.L Gore & Associates, Inc. (U.S)
- Cordis (U.S)
- Foldax (U.S)
- Micro Interventional Devices, Incorporated (U.S)
- Cardiac Dimensions (U.S)
- HighLife Medical (France)
- Mitralign (U.S)
- Braile Biomedica (Brazil)
- JenaValve (Germany)
- Corcym (Italy)
- Xeltis (Switzerland)
- Innovheart SRL (U.S)
Research Coverage
This report studies the Structural heart devices market based on product, procedure, end users and region. It also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates the market's opportunities and challenges for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets concerning their growth trends, prospects, and contributions to the total Structural heart devices market. The report forecasts the revenue of the market segments to five major regions.
Reasons to Buy the Report
This report also includes.
- Analysis of key drivers (technological advancements), restraints (Cost of the system), challenges (regulatory policies), and opportunities (Increase in minimally invasive procedures) contributing to the growth of the Structural heart devices market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, in the Structural heart devices market.
- Market Development: Comprehensive information on the lucrative emerging markets type and region.
- Market Diversification: Exhaustive information about the growing geographies, recent developments, and investments in the Structural heart devices market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global Structural heart devices market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Key data from primary sources
- 2.1.2.2 Key industry insights
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
- 2.2.2 TOP-DOWN APPROACH
- 2.2.3 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
- 2.2.4 DEMAND-SIDE ANALYSIS
- 2.3 GROWTH FORECAST
- 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.5 MARKET SHARE ANALYSIS
- 2.6 RESEARCH ASSUMPTIONS
- 2.7 RISK ASSESSMENT
- 2.8 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 STRUCTURAL HEART DEVICES MARKET OVERVIEW
- 4.2 NORTH AMERICA: STRUCTURAL HEART DEVICES MARKET, BY PRODUCT AND COUNTRY
- 4.3 STRUCTURAL HEART DEVICES MARKET, BY COUNTRY
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing geriatric population
- 5.2.1.2 Increasing preference for minimally invasive surgeries
- 5.2.1.3 Rising awareness about structural heart diseases
- 5.2.2 RESTRAINTS
- 5.2.2.1 High cost of devices and limited reimbursement
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Emergence of tissue-engineered heart valves
- 5.2.3.2 Expanding healthcare facilities in emerging economies
- 5.2.4 CHALLENGES
- 5.2.4.1 Regulatory and approval challenges
- 5.2.4.2 Intense competition among market players
- 5.2.4.3 Lack of skilled professionals
- 5.3 INDUSTRY TRENDS
- 5.3.1 MINIMALLY INVASIVE PROCEDURES
- 5.3.2 TECHNOLOGICAL ADVANCEMENTS IN DEVICE DESIGN
- 5.3.3 AI AND MACHINE LEARNING INTEGRATION
- 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
- 5.5 PRICING ANALYSIS
- 5.5.1 AVERAGE SELLING PRICE TREND, BY REGION
- 5.5.2 AVERAGE SELLING PRICE, BY KEY PLAYER
- 5.6 VALUE CHAIN ANALYSIS
- 5.7 SUPPLY CHAIN ANALYSIS
- 5.8 ECOSYSTEM ANALYSIS
- 5.9 INVESTMENT AND FUNDING SCENARIO
- 5.10 TECHNOLOGY ANALYSIS
- 5.10.1 KEY TECHNOLOGIES
- 5.10.1.1 Transcatheter aortic valve replacement
- 5.10.1.2 Transcatheter mitral aortic valve replacement
- 5.10.2 COMPLEMENTARY TECHNOLOGIES
- 5.11 PATENT ANALYSIS
- 5.12 TRADE ANALYSIS
- 5.12.1 HS CODES
- 5.12.2 EXPORT DATA
- 5.12.3 IMPORT DATA
- 5.13 KEY CONFERENCES AND EVENTS, 2024-2025
- 5.14 CASE STUDY ANALYSIS
- 5.14.1 SAPIEN 3 TRANSCATHETER HEART VALVE FOR PRECISION PLACEMENT
- 5.14.2 MITRACLIP TRANSCATHETER EDGE-TO-EDGE REPAIR TO REDUCE HOSPITALIZATION
- 5.14.3 WATCHMAN FLX DEVICE FOR LEFT ATRIAL APPENDAGE
- 5.15 REGULATORY LANDSCAPE
- 5.15.1 REGULATORY ANALYSIS
- 5.15.1.1 North America
- 5.15.1.1.1 US
- 5.15.1.1.2 Canada
- 5.15.1.2 Europe
- 5.15.1.3 Asia Pacific
- 5.15.1.3.1 Japan
- 5.15.1.3.2 China
- 5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.16 PORTER'S FIVE FORCE ANALYSIS
- 5.16.1 THREAT OF NEW ENTRANTS
- 5.16.2 THREAT OF SUBSTITUTES
- 5.16.3 BARGAINING POWER OF SUPPLIERS
- 5.16.4 BARGAINING POWER OF BUYERS
- 5.16.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.17.1 KEY STAKEHOLDERS
- 5.17.2 BUYING CRITERIA
- 5.18 REIMBURSEMENT ANALYSIS
- 5.19 UNMET NEEDS AND END-USER EXPECTATIONS
- 5.19.1 UNMET NEEDS
- 5.19.2 END-USER EXPECTATIONS
- 5.20 IMPACT OF AI/GEN AI ON STRUCTURAL HEART DEVICES MARKET
- 5.20.1 INTRODUCTION
- 5.20.2 KEY COMPANIES IMPLEMENTING AI
- 5.20.3 MARKET POTENTIAL OF AI IN STRUCTURAL HEART DEVICES MARKET
6 STRUCTURAL HEART DEVICES MARKET, BY PROCEDURE
- 6.1 INTRODUCTION
- 6.2 REPLACEMENT PROCEDURES
- 6.2.1 TAVR/TAVI REPLACEMENT PROCEDURES
- 6.2.1.1 Quicker recuperation and shorter hospital stays to promote growth
- 6.2.2 SAVR PROCEDURES
- 6.2.2.1 Wide adoption for treating valvular heart diseases to sustain growth
- 6.3 REPAIR PROCEDURES
- 6.3.1 CLOSURE PROCEDURES
- 6.3.1.1 Increasing prevalence of structural heart defects to boost market
- 6.3.2 ANNULOPLASTY
- 6.3.2.1 Growing focus on safety and efficacy to drive market
- 6.3.3 VALVULOPLASTY
- 6.3.3.1 Increasing cases of aortic stenosis and valvular regurgitation to fuel market
- 6.3.4 TMVR PROCEDURES
- 6.3.4.1 Growing preference over valve replacement to promote growth
- 6.3.5 TEER PROCEDURES
- 6.3.5.1 Global prevalence of mitral regurgitation to expedite growth
7 STRUCTURAL HEART DEVICES MARKET, BY PRODUCT
- 7.1 INTRODUCTION
- 7.2 HEART VALVE DEVICES
- 7.2.1 TRANSCATHETER HEART VALVES
- 7.2.1.1 Transcatheter mitral valve replacement
- 7.2.1.1.1 Growing use in treating age-related degeneration and heart diseases to boost market
- 7.2.1.2 Transcatheter aortic valve replacement
- 7.2.1.2.1 Increasing instances of aortic valve replacement to aid growth
- 7.2.2 SURGICAL VALVES
- 7.2.2.1 Mechanical valves
- 7.2.2.1.1 Higher durability and affordability to encourage growth
- 7.2.2.2 Biological valves
- 7.2.2.2.1 Need for reduced incidence of bleeding to accelerate growth
- 7.3 OCCLUDERS, CLOSURE SYSTEMS, AND DELIVERY SYSTEMS
- 7.4 ANNULOPLASTY RINGS
- 7.4.1 HIGH PREVALENCE OF MITRAL AND TRICUSPID VALVE REGURGITATION DISEASES TO PROMOTE GROWTH
- 7.5 ACCESSORIES
- 7.5.1 CATHETERS
- 7.5.1.1 Growing preference for minimally invasive procedures to fuel market
- 7.5.2 GUIDEWIRES
- 7.5.2.1 Need for precise navigation and placement of medical devices to augment growth
- 7.5.3 SHEATHS
- 7.5.3.1 Need for minimizing vascular trauma to promote growth
- 7.5.4 OTHER ACCESSORIES
8 STRUCTURAL HEART DEVICES MARKET, BY END USER
- 8.1 INTRODUCTION
- 8.1.1 HOSPITALS
- 8.1.1.1 Ability to handle large volume of patients to boost market
- 8.1.2 AMBULATORY SURGICAL CENTRES
- 8.1.2.1 Faster procedure time and lower infection rates to drive market
- 8.1.3 OTHER END USERS
9 STRUCTURAL HEART DEVICES MARKET, BY REGION
- 9.1 INTRODUCTION
- 9.2 NORTH AMERICA
- 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 9.2.2 US
- 9.2.2.1 Favorable reimbursement scenario to augment growth
- 9.2.3 CANADA
- 9.2.3.1 Rising prevalence of target diseases to drive market
- 9.3 EUROPE
- 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 9.3.2 GERMANY
- 9.3.2.1 Increase in geriatric and obese population to stimulate growth
- 9.3.3 UK
- 9.3.3.1 Increasing incidence of peripheral vascular diseases to support growth
- 9.3.4 FRANCE
- 9.3.4.1 Favorable government initiatives to drive market
- 9.3.5 ITALY
- 9.3.5.1 Increasing health expenditure and rising diabetes prevalence to boost market
- 9.3.6 SPAIN
- 9.3.6.1 Growing geriatric population to propel market
- 9.3.7 REST OF EUROPE
- 9.4 ASIA PACIFIC
- 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 9.4.2 JAPAN
- 9.4.2.1 Increasing healthcare expenditure to boost market
- 9.4.3 CHINA
- 9.4.3.1 Growing target patient population to drive market
- 9.4.4 INDIA
- 9.4.4.1 Increasing prevalence of diabetes to expedite growth
- 9.4.5 AUSTRALIA
- 9.4.5.1 Growing hospitalizations due to coronary artery diseases to fuel market
- 9.4.6 SOUTH KOREA
- 9.4.6.1 Increasing prevalence of hypertension to support growth
- 9.4.7 REST OF ASIA PACIFIC
- 9.5 LATIN AMERICA
- 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 9.5.2 BRAZIL
- 9.5.2.1 Rising healthcare expenditure to aid growth
- 9.5.3 MEXICO
- 9.5.3.1 Increasing prevalence of cardiovascular diseases to spur growth
- 9.5.4 REST OF LATIN AMERICA
- 9.6 MIDDLE EAST & AFRICA
- 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 9.6.2 GCC COUNTRIES
- 9.6.2.1 Rising cases of hypertension and associated cardiovascular diseases to drive market
- 9.6.3 REST OF MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
- 10.1 INTRODUCTION
- 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
- 10.3 REVENUE ANALYSIS, 2019-2023
- 10.4 MARKET SHARE ANALYSIS, 2023
- 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 10.5.1 STARS
- 10.5.2 EMERGING LEADERS
- 10.5.3 PERVASIVE PLAYERS
- 10.5.4 PARTICIPANTS
- 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 10.5.5.1 Company footprint
- 10.5.5.2 Product footprint
- 10.5.5.3 Procedure footprint
- 10.5.5.4 End-user footprint
- 10.5.5.5 Region footprint
- 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 10.6.1 PROGRESSIVE COMPANIES
- 10.6.2 DYNAMIC COMPANIES
- 10.6.3 RESPONSIVE COMPANIES
- 10.6.4 STARTING BLOCKS
- 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 10.7 BRAND/PRODUCT COMPARISON
- 10.8 COMPANY VALUATION AND FINANCIAL METRICS
- 10.8.1 FINANCIAL METRICS
- 10.8.2 COMPANY VALUATION
- 10.9 COMPETITIVE SCENARIO
- 10.9.1 PRODUCT LAUNCHES AND APPROVALS
- 10.9.2 DEALS
11 COMPANY PROFILES
- 11.1 KEY PLAYERS
- 11.1.1 EDWARDS LIFESCIENCES CORPORATION
- 11.1.1.1 Business overview
- 11.1.1.2 Products offered
- 11.1.1.3 Recent developments
- 11.1.1.4 MnM view
- 11.1.1.4.1 Right to win
- 11.1.1.4.2 Strategic choices
- 11.1.1.4.3 Weaknesses and competitive threats
- 11.1.2 MEDTRONIC
- 11.1.2.1 Business overview
- 11.1.2.2 Products offered
- 11.1.2.3 Recent developments
- 11.1.2.3.1 Product launches and approvals
- 11.1.2.3.2 Deals
- 11.1.2.4 MnM view
- 11.1.2.4.1 Right to win
- 11.1.2.4.2 Strategic choices
- 11.1.2.4.3 Weaknesses and competitive threats
- 11.1.3 ABBOTT
- 11.1.3.1 Business overview
- 11.1.3.2 Products offered
- 11.1.3.3 Recent developments
- 11.1.3.3.1 Product launches and approvals
- 11.1.3.3.2 Deals
- 11.1.3.4 MnM view
- 11.1.3.4.1 Right to win
- 11.1.3.4.2 Strategic choices
- 11.1.3.4.3 Weaknesses and competitive threats
- 11.1.4 BOSTON SCIENTIFIC CORPORATION
- 11.1.4.1 Business overview
- 11.1.4.2 Products offered
- 11.1.4.3 Recent developments
- 11.1.4.3.1 Product launches and approvals
- 11.1.5 TELEFLEX
- 11.1.5.1 Business overview
- 11.1.5.2 Products offered
- 11.1.5.3 Recent developments
- 11.1.5.3.1 Product launches and approvals
- 11.1.5.3.2 Deals
- 11.1.6 INTEGER HOLDINGS CORPORATION
- 11.1.6.1 Business overview
- 11.1.6.2 Products offered
- 11.1.6.3 Recent developments
- 11.1.6.3.1 Deals
- 11.1.6.3.2 Expansions
- 11.1.7 LEPU MEDICAL TECHNOLOGY CO., LTD.
- 11.1.7.1 Business overview
- 11.1.7.2 Products offered
- 11.1.7.3 Recent developments
- 11.1.7.3.1 Product launches and approvals
- 11.1.8 TTK HEALTHCARE
- 11.1.8.1 Business overview
- 11.1.8.2 Products offered
- 11.1.9 ARTIVION, INC.
- 11.1.9.1 Business overview
- 11.1.9.2 Products offered
- 11.1.10 VENUS MEDTECH (HANGZHOU) INC.
- 11.1.10.1 Business overview
- 11.1.10.2 Products offered
- 11.1.10.3 Recent developments
- 11.1.10.3.1 Product launches and approvals
- 11.1.11 LIFETECH SCIENTIFIC CORPORATION
- 11.1.11.1 Business overview
- 11.1.11.2 Products offered
- 11.1.12 COOK
- 11.1.12.1 Business overview
- 11.1.12.2 Products offered
- 11.1.12.3 Recent developments
- 11.1.13 CORDIS
- 11.1.13.1 Business overview
- 11.1.13.2 Products offered
- 11.1.13.3 Recent developments
- 11.1.13.3.1 Product launches and approvals
- 11.1.14 SMT
- 11.1.14.1 Business overview
- 11.1.14.2 Products offered
- 11.1.14.3 Recent developments
- 11.1.14.3.1 Other developments
- 11.1.15 MERIL LIFE SCIENCES PVT. LTD.
- 11.1.15.1 Business overview
- 11.1.15.2 Products offered
- 11.1.16 W. L. GORE & ASSOCIATES, INC.
- 11.1.16.1 Business overview
- 11.1.16.2 Products offered
- 11.2 OTHER PLAYERS
- 11.2.1 FOLDAX
- 11.2.2 MICRO INTERVENTIONAL DEVICES, INCORPORATED
- 11.2.3 CARDIAC DIMENSIONS
- 11.2.4 BIOTRONIK
- 11.2.5 HIGHLIFE MEDICAL
- 11.2.6 MITRALIGN
- 11.2.7 BRAILE BIOMEDICA
- 11.2.8 JENAVALVE
- 11.2.9 CORCYM
- 11.2.10 XELTIS
- 11.2.11 INNOVHEART SRL
12 APPENDIX
- 12.1 DISCUSSION GUIDE
- 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 12.3 CUSTOMIZATION OPTIONS
- 12.4 RELATED REPORTS
- 12.5 AUTHOR DETAILS
